Marta E. Wosińska
Marta E. Wosińska, PhD, is the Director of Economics. She comes to FTC from Duke University where she was Consulting Professor and Deputy Director, Policy at the Duke-Margolis Center for Health Policy.
Dr. Wosińska’s experience spans both academia as well as the executive and legislative branches of the federal government. In 2019, Dr. Wosińska served as an economic advisor to the US Senate Finance Committee, providing drug market analysis and expert guidance for the Committee’s bipartisan investigative and legislative work on drug pricing. Her executive branch tenure includes positions as Chief Healthcare Economist in the Health and Human Services Office of Inspector General, Director of Economics Staff at Food and Drug Administration’s Center for Drug Evaluation and Research and Senior Economic Advisor to FDA’s Deputy Commissioner for Medical Products and Tobacco.
Before entering public service, Dr. Wosińska was an Assistant Professor of Marketing at the Harvard Business School and visiting Assistant Professor at the Columbia Business School. Dr. Wosińska received her PhD in economics from University of California at Berkeley and a bachelor’s degree from Arizona State University.
- Nitzan Arad, Marianne Hamilton-Lopez, Rebecca Ray, Adam Kroetsch, Susan Dentzer, Mark McClellan, Marta Wosińska (2021) “Realizing the Benefits of Biosimilars: What the U.S. Can Learn from Europe,” Duke-Margolis White Paper
- Janet Woodcock and Marta Wosińska (2013) “Economic and Technological Drivers of Generic Sterile Injectable Drug Shortages,” Clinical Pharmacology and Therapeutics
- Samuel Kina and Marta Wosińska (2009) “Pharmaceutical Pricing” chapter in the Handbook of Research in Pricing, ed. Vithala Rao
- Marta Wosińska (2005) “Direct‐to‐Consumer Advertising and Drug Therapy Compliance,” Journal of Marketing Research
- Leslie Eldenburg, Benjamin Hermalin, Michael Weisbach, and Marta Wosińska (2004) “Hospital Governance, Performance Objectives, and Organizational Form,” Journal of Corporate Finance